《港樓》清水灣傲瀧錄兩宗交易告吹個案 料涉殺訂總額約1,502萬
新世界發展(00017.HK)旗下西貢清水灣傲瀧,新近錄得兩宗交易告吹個案,料涉殺訂總額約1,502萬元。
成交紀錄冊顯示,傲瀧A座5室,實用面積2,955平方呎連平台及天台特色戶,原於2020年以1.0227億元售出,實呎3.46萬元,買家當時採用1,440日、即約4年特長成交期,惟目前顯示已終止買賣合約,已支付的10%訂金、即約1,022萬元料遭沒收,為本月涉殺訂額最多的單一撻大訂個案。
另外,第12座地下B室,實用1,730平方呎連花園特色戶,原於2019年以4793.9萬元售出,實呎2.77萬元,買家同樣採用1,440日即約4年特長成交期,現終止買賣合約,已支付的10%訂金、涉約479萬元料遭沒收。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.